-
Beigene-283 jointly developed by Baiji Shenzhou and Merck xuelanuo enters phase I clinical
Time of Update: 2020-04-03
On May 5, beigene-283 jointly developed by Baiji Shenzhou and Merck Serono entered phase I clinical practice, and Baiji Shenzhou won 5 million USD mileage gold
Beigene
-
Ivertinib, the original drug of Essen medicine, has initial clinical effect and breaks through the difficult problem of targeted treatment of lung cancer
Time of Update: 2020-04-03
In the next key clinical study of ivetinib, Wu Yilong said that the clinical study will verify the results achieved in phase I, shorten the market time of the drug, and benefit more lung cancer patients with greater welfare.
-
Chinese and American researchers found that the combination of diphosphonic acid and rapamycin can treat drug-resistant lung cancer
Time of Update: 2020-04-03
Zhang Yonghui said that the two kinds of drugs have a strong synergistic effect in the body, and will work together to kill the cancer cells mutated by KRAS.
-
Biorxiv: Chinese scientists reveal the potential T cell and B cell epitopes of 2019 ncov
Time of Update: 2020-02-26
The researchers identified 405 viral peptides with good antigen expression scores in human MHC-I and MHC-II alleles, and found two potential neutralizing B cell epitopes (440-460 and 494-506) near the receptor binding domain of 2019-ncov s protein.
-
Nature: researchers discover new genetic diseases
Time of Update: 2020-02-24
February 24, 2020 / BIOON / -- research started from zebrafish has now pointed out the role of collagen secretion in various clinical symptoms, as well as in a newly discovered
-
Many articles focus on important research results of mitochondria
Time of Update: 2020-02-23
In this paper, I have compiled many important research results, and jointly interpreted the new progress of scientists in the field of mitochondrial research, to share with you
-
Tumor specific cytoplasmic targeting of Ras mutants can inhibit tumor growth
Time of Update: 2020-02-20
Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor.
-
Science subjournal: tumor specific antibody targeted inhibition of Ras mutant tumors
Time of Update: 2020-02-20
Injecting inras37 into mice with small rasmut xenograft tumor by systemic administration can produce strong antitumor activity, but this antibody has little effect on the downstream rasmut tumor with simultaneous PI3K mutation, which can be overcome by combining PI3K inhibitor.
-
Nat cancer: prediction of the response of lung cancer patients to immunotherapy by multimodal genome analysis
Time of Update: 2020-02-17
February 17, 2020 / biool / -- researchers from Kimmel Cancer Center, Johns Hopkins, Bloomberg Kimmel Cancer Immunotherapy Institute and Johns Hopkins University School of medicine
-
Nat Commun: how cancer and the immune system compete in arms! In depth interpretation
Time of Update: 2020-02-17
February 18, 2020 / BIOON / -- recently, an international journal Nature Communications In the previous research report, scientists from London Cancer Research Institute and other
-
The origin of autoimmune diseases has been revealed: it is the "hooligan" immune cells that are playing tricks
Time of Update: 2020-02-17
Through analysis, the researchers found that the pathogenic immune cells of patients with vasculitis had accumulated a large number of mutations before producing rheumatoid factors.
-
Gene therapy for Gaucher's disease! American FDA awarded avr-rd-02 orphan drug qualification and rare pediatric disease qualification
Time of Update: 2020-02-16
Recently, the company announced that the U.S. Food and Drug Administration (FDA) has granted its gene therapy pr001 to treat patients with Gaucher disease (GD) orphan drug qualification (odd).
-
Cell: research reveals the "origin" of autoimmune diseases
Time of Update: 2020-02-15
February 15, 2020 / BIOON / -- recently, researchers from Garvan Medical Research Institute have identified the types of single cells that cause autoimmune diseases from patients
-
Nat Med: genetic variation may help prevent Alzheimer's disease
Time of Update: 2020-02-14
The researchers suspect that carrying two copies of the apoe3ch variant may delay the clinical onset of Alzheimer's disease by limiting tau pathology and neurodegeneration.
-
Uncovering the mysteries of mitochondrial genome may help to develop a variety of new cancer therapies
Time of Update: 2020-02-14
Because mitochondria play a key role in tumorigenesis, in-depth research on mitochondrial genome is essential to reveal the mechanism of tumorigenesis and develop new therapies.
-
Ahead of Merck! Captatinib, a specific subtype of Novartis lung cancer treatment drug, has been given priority by FDA
Time of Update: 2020-02-13
Carmatinib is currently being evaluated in patients with locally advanced or non-small cell lung cancer (NSCLC) with metastatic met exon 14 leap (metex14) mutations for first-line and prior treatment.
-
Nature: discovery of a new anticancer drug for key mutations of tumor
Time of Update: 2020-02-13
February 13, 2020 / biourn / -- a research team from several institutions in the United States and Australia found that a drug optimized for a protein produced due to genome mutation can reduce some tumors in mice and humans.
-
To solve the mystery of tumor hijacking nerve cells, scientists have discovered the anti-cancer potential of antihypertensive drugs
Time of Update: 2020-02-13
▲ blocking adrenergic signal slows down the growth of p53 mutant cancer cells (picture source: reference [2]) The importance of this research is highly valued in nature.
-
So far, the most complete cancer gene map is expected to identify tumor mutations decades in advance
Time of Update: 2020-02-12
The pan cancer project explored the remaining 99% of the genome in more detail, including key areas controlling gene switches, similar to mapping the interior of the continent.
-
Captatinib, a specific subtype of Novartis lung cancer treatment drug, has been given priority by FDA
Time of Update: 2020-02-12
Compiling coco On February 11, Novartis announced that the U.S
FDA accepted the new drug application (NDA) of capmatinib (inc280), and granted priority review
